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Background: In mammalians, HIF is a master regulator of hypoxia gene expression through direct binding to DNA,
while its role in microRNA expression regulation, critical in the hypoxia response, is not elucidated genome wide.
Our aim is to investigate in depth the regulation of microRNA expression by hypoxia in the breast cancer cell line
MCF-7, establish the relationship between microRNA expression and HIF binding sites, pri-miRNA transcription and
microRNA processing gene expression.
Methods: MCF-7 cells were incubated at 1% Oxygen for 16, 32 and 48 h. SiRNA against HIF-1α and HIF-2α
were performed as previously published. MicroRNA and mRNA expression were assessed using microRNA
microarrays, small RNA sequencing, gene expression microarrays and Real time PCR. The Kraken pipeline was
applied for microRNA-seq analysis along with Bioconductor packages. Microarray data was analysed using
Limma (Bioconductor), ChIP-seq data were analysed using Gene Set Enrichment Analysis and multiple testing
correction applied in all analyses.
Results: Hypoxia time course microRNA sequencing data analysis identified 41 microRNAs significantly up- and
28 down-regulated, including hsa-miR-4521, hsa-miR-145-3p and hsa-miR-222-5p reported in conjunction with
hypoxia for the first time. Integration of HIF-1α and HIF-2α ChIP-seq data with expression data showed overall
association between binding sites and microRNA up-regulation, with hsa-miR-210-3p and microRNAs of
miR-27a/23a/24-2 and miR-30b/30d clusters as predominant examples. Moreover the expression of hsa-miR-27a-3p and
hsa-miR-24-3p was found positively associated to a hypoxia gene signature in breast cancer. Gene expression analysis
showed no full coordination between pri-miRNA and microRNA expression, pointing towards additional levels of
regulation. Several transcripts involved in microRNA processing were found regulated by hypoxia, of which DICER
(down-regulated) and AGO4 (up-regulated) were HIF dependent. DICER expression was found inversely correlated
to hypoxia in breast cancer.
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Conclusions: Integrated analysis of microRNA, mRNA and ChIP-seq data in a model cell line supports the hypothesis
that microRNA expression under hypoxia is regulated at transcriptional and post-transcriptional level, with the presence
of HIF binding sites at microRNA genomic loci associated with up-regulation. The identification of hypoxia and HIF
regulated microRNAs relevant for breast cancer is important for our understanding of disease development and design
of therapeutic interventions.
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Hypoxia plays an important role in cancer, where the
oxygen supply can be affected by tumour growth and
subsequent alteration of the blood vessel network, leading
to fatal consequences such as cell resistance to certain
drugs and metastasis (reviewed in [1]). Under low cellular
oxygen levels, the hypoxic inducible family of transcrip-
tion factors (HIF) drive a complex transcriptional re-
sponse that affects several biological processes relevant
for the fate of the cells under these conditions, including
glycolysis, angiogenesis and apoptosis [2]. HIF transcrip-
tion factors are heterodimers composed of an alpha and a
beta subunit. There are three HIF-alpha subunits, of
which HIF-1α and HIF-2α have been shown to have
important regulatory roles in the hypoxia response. HIF-
alpha protein levels are regulated by the Von Hippel
Lindau (VHL) protein which mediates the ubiquitination
of HIF-alpha by specifically recognising and binding to
two prolyl-hydroxylated residues, resulting on a rapid
elimination of HIF-alpha. HIF-alpha prolyl hydroxyl-
ation is catalysed by three homologous 2-oxoglutarate
dependent dioxygenases, PHD1, PHD2 and PHD3. Fur-
ther control of HIF-alpha expression is performed by
another dioxygenase: Factor Inhibiting HIF 1 (FIH-1).
FIH-1 catalyses the formation of a specific hydroxyas-
paraginyl residue in HIF-alpha that reduces its binding
to the transcriptional coactivator p300 (for a review see
[3,4]). Since the hydroxylation of HIF-alpha residues by
PHDs and FIH is oxygen dependent, HIF-alpha is able
to escape VHL recognition and further proteasomal
degradation under hypoxic conditions, bind to p300
and HIF-beta and induce transcriptional changes that
also affect microRNAs.
MicroRNAs are small noncoding RNA oligonucleo-
tides (~22 nucleotides) that regulate gene expression at
post-transcriptional level. Their genomic organisation is
heterogeneous. For instance approximately half of the
microRNAs identified in mammals are found in inter-
genic regions whereas the other half are encoded within
the open reading frame of other genes [5,6]. Neverthe-
less some microRNAs belonging to this last group have
their own promoter. In addition microRNAs can be
transcribed alone or in polycistronic units [7]. Independ-
ent of their origin, all microRNA transcripts undergo acomplex process of biogenesis which takes part in differ-
ent cellular compartments and involves many proteins.
Briefly, first a microRNA containing transcript (pri-miRNA)
is cleaved in the nucleus by a complex lead by DROSHA
and DGCR8, generating 70-nucleotide long RNA mole-
cules known as precursor microRNAs (pre-miRNAs).
Pre-miRNAs are transported by EXPORTIN 5 from the
nucleus to the cytoplasm where they are cleaved by
DICER/TRBP complex, producing a 22 nucleotide micro-
RNA duplex. This microRNA duplex is then loaded into
the RNA-induced silencing complex (RISC) where
ARGONAUTE (AGO) proteins have a key role on the
recruitment of microRNAs and their mRNA targets.
Finally one strand from the duplex mediates the regula-
tion of target mRNAs by impairing their translation
and/or by promoting their degradation. In most cases,
there is a preference for the selection of one of the strands
of the microRNA duplex in the RISC complex since both
strands are detected at very assymetric levels, (for a review
see [8]). Most of the earlier studies have focused on the
most abundant strand (usually 5p), whereas the less
abundant strand (also known as miRNA*) is considered
to be degraded. However evidence is growing that
miRNA* can actually be functional by regulating specific
target mRNA [9,10]. Indeed, a mature miRNA is now
designated with the suffix “-3p” or “-5p” depending on
the originating strand and we have used the same
nomenclature in this work.
Several studies have been performed in cancer cell
lines, endothelial cell lines and primary human cytotro-
phoblasts that have identified microRNAs regulated by
hypoxia [11-20]. Most of these studies were done using
microarray or Real time PCR (qPCR) based platforms,
thus limiting the findings to a set of microRNAs. The
overlap between the microRNAs found significantly reg-
ulated in these studies is low, probably due to the high
variability generated by the fact of using different cell
types, different experimental conditions and different
technologies for measuring microRNA expression. The
role of HIF in the regulation of microRNA expression
has not been deeply investigated and only for a few
microRNAs there is some experimental evidence that
HIF is directly involved in the regulation of their expres-
sion under hypoxia [16,21-23]. Also some elements of
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reported to be regulated under hypoxia [14,18,24], but
the direct involvement of HIF through DNA binding
remains mostly unknown. The first screenings for hyp-
oxia regulated microRNAs in breast cancer and other
solid tumours, suggested that hypoxia could be a key
factor in microRNA modulation in cancer [16]. Moreover,
some hypoxia regulated microRNAs have been shown to
have functional roles that are of great relevance in cancer.
Therefore, it is important to shed more light in this area.
Our aim is to investigate the regulation of microRNA
expression by hypoxia, with a special focus in the role of
HIF in this process. We have chosen the breast cancer
cell line MCF-7 as a system because we have already
shown that the HIF-1α and HIF-2α proteins are present
and stabilized across different hypoxia time points, start-
ing at 16 h, and we have characterised the role of both
HIF-1α and HIF-2α in the regulation of gene expression
in this system [25,26]. We have performed a comprehen-
sive study, by integrating microRNA expression, gene
expression and HIF-1α and HIF-2α chromatin immuno-
precipitation (ChIP) data from the same breast cancer
cell line MCF-7. We have used the latest next generation
sequencing technology as well as established microarrays
to generate microRNA expression profiles from a three
point time course in hypoxia (16 h, 32 h and 48 h). We
present here microRNAs that are found consistently reg-
ulated at different hypoxia time points, including novel
hypoxia related microRNAs. Moreover, we have used
gene expression profiles to assess the relationship between
microRNA and host gene for the microRNAs located in
intragenic regions and HIF-1α and HIF-2α ChIP-seq data
to identify binding sites close to microRNAs. Finally we
also used these data sets to investigate the expression of
the genes involved in the microRNA processing pathway
and the involvement of HIF in their regulation.
Results
Profiling the population of microRNAs in hypoxic MCF-7
cells by next-generation sequencing
The total number of sequencing reads obtained was in
the range between 32 and 35 million reads per sample.
After filtering, sequencing reads with a length between
18 and 26 nucleotides represented 75.2-87.5% of total
number of reads obtained initially (Additional file 1:
Table S1). On average, 99% of these reads (98.9-99.5%)
were mapped to the human genome using Bowtie, from
which 75-85.9% had a unique mapping position (Additional
file 1: Table S1). Most of the reads mapped to annotated
regions (98-98.9%), and as expected the vast majority of
them matched genomic regions allocating microRNAs
(94.5-96.1% of reads mapped to annotated regions). The
residual fraction of mapped reads not corresponding to
microRNAs was distributed among a miscellanea ofannotated regions including other RNA and small
RNAs species, protein coding exons, pseudogenes and
repeat molecules (Additional file 1: Table S1).
We were able to identify 502 microRNAs consistently
across all conditions in MCF-7 cells (Additional file 1:
Table S2). Among them, 412 microRNAs had strand
(-5p/-3p) annotations with 53.2% of 5p and 46.8% of
3p-microRNAs. We found that 184 microRNAs were
from only one strand (either-5p or-3p), so there were no
detectable traces of the other hairpin arm and 114
microRNAs have both the 5p and 3p strands expressed.
The sequencing data also allowed us to identify pre-
cursors on different genomic loci that generate the same
mature microRNA. For six mature microRNAs (hsa-let-
7f-5p, hsa-miR-16-5p, hsa-miR-181a-5p, hsa-miR-24-3p,
hsa-miR-29b-3p and hsa-miR-30c-5p) we were able to
identify microRNAs from the other strand derived from
the two different precursors. These findings provide
evidence that both loci of these particular microRNAs
would be expressed in MCF-7 cells. Compared to a
similar sequencing based study performed using human
umbilical vein endothelial cells (HUVEC) [17], there
was an overlap of 80 microRNA sequences.Differential expression of microRNAs under hypoxia in
MCF-7 cells
When looking at differential expression between hypoxia
and normoxia, we found that the number of differentially
expressed microRNAs increased along the time of ex-
posure to hypoxia. We identified 1, 49 and 69 micro-
RNAs up-regulated at 16 h, 32 h and 48 h of hypoxia
respectively (adj.p-val ≤ 0.05) whereas 4, 37 and 50
microRNAs were detected as down-regulated at 16 h,
32 h and 48 h of hypoxia respectively (adj.p-val ≤ 0.05)
(see Figure 1A). Among each group of significant micro-
RNAs we found microRNAs from both 5p and 3p strands.
All microRNAs significantly changing in expression
levels after 16 h of hypoxia remained altered in the same
direction across the time course: the up-regulated hsa-
miR-210-3p and the down-regulated hsa-miR-4521, hsa-
miR-145-3p and hsa-miR-222-5p were also significantly
up- and down-regulated, respectively, after 32 h and 48 h
of hypoxia whereas the down-regulated hsa-miR-29b-1-5p
remained significantly decreased after 32 h of hypoxia but
not 48 h (Figure 1A and Tables 1 and 2). The number of
significantly up- or down-regulated microRNAs increases
substantially at 32 and 48 h of hypoxia, with a consider-
able overlap between these time points: 40 and 24
microRNAs were found to be significantly up-regulated
and down-regulated, respectively, at both hypoxia time
points (Figure 1A and Tables 1 and 2, adj.p-val < 0.05).
The induction of HIF protein levels across the hypoxia
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Figure 1 Hypoxia regulated microRNAs in MCF-7 cells. microRNA sequencing data generated from a hypoxia time course in MCF-7 (16, 32 and
48 h at 1% Oxygen) was analysed and the overlap between the microRNAs found significantly up- or down-regulated at each time point compared to
normoxia control (adj.p-val <0.05) has been represented in Venn diagrams (A). The levels of HIF-1α and HIF-2α were measured by immunoblotting
across the hypoxia time course (H16h, H32h, H48h) and normoxia (N), with beta-actin used as a control (B). The down-regulation of miR-4521,
miR-145-3p and miR-222-5p in hypoxia was validated by qPCR (C). Fold-changes (in linear scale) obtained for each microRNA at each time
point relative to normoxia control are represented in boxplots (*significant fold-change compared to normoxia after ANOVA followed by pairwise
t-test, adj.p-val ≤ 0.05). The expression of miR-145-5p and miR-222-3p was also assessed by qPCR, confirming a different pattern of expression as
compared to their counterpart strands.
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at 32 h of hypoxia and drop at 48 h (see Figure 1B).
We have previously demonstrated the up-regulation of
hsa-miR-210-3p (previously annotated as hsa-miR-210)
across a hypoxia time course in MCF-7 cells [27], but this
in depth study has revealed a number of hypoxia regulatedmicroRNAs that have not been reported in previous
studies [11-20] (highlighted in bold in Tables 1 and 2).
Agilent microRNA microarrays (3 biological replicates
per condition) were also used to complement and validate
the sequencing data in a broad manner, as the two tech-
nologies have their own strengths and weaknesses in
Table 1 MicroRNAs found significantly up-regulated in MCF7 cells exposed to hypoxia by analysis of microRNA-seq data
MicroRNAs significantly up-regulated in hypoxia at 16, 32 and 48 h (adj.p-val ≤ 0.05)
microRNAs FC H16h adj.p-val FC H32h adj.p-val FC H48h adj.p-val
hsa-miR-210-3p 3.24 0.0001 4.03 5.46e-07 3.96 8.41e-07
MicroRNAs significantly up-regulated in hypoxia at 32 and 48 h (adj.p-val ≤ 0.05)
microRNAs FC H16h adj.p-val FC H32h adj.p-val FC H48h adj.p-val
hsa-miR-1 1.86 0.4806 2.25 0.026223 3.12 0.000682
hsa-miR-106b-3p 1.10 0.9629 2.15 0.029336 1.94 0.048003
hsa-miR-1246 1.53 0.9046 5.08 0.000085 3.87 0.001346
hsa-miR-1269a 1.18 0.9399 2.43 0.005459 1.94 0.033244
hsa-miR-140-3p 1.11 0.9629 2.21 0.016949 2.01 0.027275
hsa-miR-141-5p 1.26 0.9046 1.78 0.049237 1.93 0.018787
hsa-miR-143-3p 1.82 0.2553 2.80 0.000136 1.90 0.021242
hsa-miR-151a-3p 1.35 0.9046 2.47 0.014476 2.34 0.016879
hsa-miR-181c-3p 1.12 0.9629 1.89 0.038509 1.84 0.035990
hsa-miR-192-5p 1.33 0.8665 2.14 0.009894 2.24 0.003741
hsa-miR-194-5p 1.09 0.9629 1.96 0.042635 2.28 0.008532
hsa-miR-195-3p 1.18 0.9555 2.49 0.007142 2.29 0.012846
hsa-miR-203a 1.21 0.9242 1.93 0.039759 1.93 0.030635
hsa-miR-215-5p 1.28 0.9046 2.92 0.001669 2.23 0.017671
hsa-miR-27a-5p 1.22 0.9046 1.90 0.026536 2.19 0.003759
hsa-miR-28-3p 0.97 0.9774 2.15 0.021442 2.04 0.025454
hsa-miR-3065-3p 1.27 0.9046 2.13 0.017787 2.67 0.000890
hsa-miR-30d-5p 1.24 0.9046 2.38 0.005459 3.31 0.000050
hsa-miR-30d-3p 1.43 0.8010 2.04 0.018042 1.80 0.041199
hsa-miR-30e-3p 1.26 0.9046 2.00 0.033309 2.35 0.005147
hsa-miR-3140-3p 1.13 0.9629 2.17 0.049237 2.31 0.025454
hsa-miR-3158-3p 2.19 0.0594 3.29 0.000032 2.65 0.000730
hsa-miR-338-5p 1.15 0.9604 2.11 0.018185 2.72 0.000672
hsa-miR-33b-5p 1.27 0.9046 2.87 0.000509 1.97 0.025454
hsa-miR-203b-3p 1.18 0.9555 2.11 0.047389 2.26 0.023495
hsa-miR-3619-3p 1.30 0.9242 3.11 0.004682 4.15 0.000159
hsa-miR-3677-3p 1.77 0.6186 2.94 0.002596 2.73 0.003759
hsa-miR-378c 1.02 0.9835 2.11 0.020104 1.88 0.040362
hsa-miR-378d 1.04 0.9629 2.39 0.013088 2.08 0.029016
hsa-miR-378i 1.38 0.8770 2.63 0.003952 2.69 0.002146
hsa-miR-3913-5p 1.06 0.9629 1.91 0.041667 2.26 0.006343
hsa-miR-3928-3p 1.22 0.9250 2.28 0.023169 2.12 0.030094
hsa-miR-4504 2.14 0.4257 2.97 0.006637 2.55 0.019065
hsa-miR-4746-5p 1.37 0.8665 2.13 0.018185 2.17 0.011517
hsa-miR-4760-5p 1.82 0.2984 2.04 0.017700 1.80 0.040620
hsa-miR-548a-3p 1.12 0.9629 2.55 0.032600 2.33 0.046620
hsa-miR-627-5p 1.44 0.8474 2.72 0.002857 2.29 0.011721
hsa-miR-92b-3p 1.19 0.9242 1.95 0.032600 2.22 0.006343
hsa-miR-942-5p 1.25 0.9046 2.08 0.016836 2.16 0.007682
hsa-miR-99b-5p 1.15 0.9629 2.39 0.018617 3.09 0.001097
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Table 1 MicroRNAs found significantly up-regulated in MCF7 cells exposed to hypoxia by analysis of microRNA-seq data
(Continued)
MicroRNAs significantly up-regulated in hypoxia by QPCR†
microRNAs FC H16h adj.p-val FC H32h adj.p-val FC H48h adj.p-val
hsa-miR-24-2-5p 1.08 ≥ 0.05 1.65 ≤ 0.05 1.81 ≤ 0.05
hsa-miR-27a-3p 1.93 ≤ 0.05 2.84 ≤ 0.05 2.02 ≤ 0.05
hsa-miR-30b-3p 1.58 ≥ 0.05 2.10 ≤ 0.05 2.40 ≤ 0.05
hsa-miR-30b-5p 1.20 ≥ 0.05 2.23 ≤ 0.05 1.81 ≤ 0.05
MicroRNAs in each section of the table are arranged in numerical order for ease of reading. Fold-change in linear scale (FC) and adjusted p value (adj.p-val) are
shown for each microRNA at each hypoxia time. MicroRNAs which regulation by hypoxia has not been reported before are highlighted in bold. Last section shows
microRNAs for which sequencing data did not produce significant results but were validated as up-regulated by qPCR (†).
Hsa-miR-27a-3p was also found significantly up-regulated across the hypoxia time course in Agilent microarray data.
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commonly detected between sequencing and microarrays
(Additional file 1: Table S3), with a significant correlation
between the number of reads and array intensity
(Spearman: 0.57 (average), p-val ≤ 0.05). When comparing
the fold changes obtained for each microRNA across the
time course in each platform there is overall a significant
correlation (Pearson: 0.30 (average), p-val ≤ 0.05). Most of
the compared microRNAs show a clear trend towards
the same direction in both platforms despite some
punctual disagreements (see Additional file 2: Figure S1).
Moreover around half of the microRNAs found signifi-
cantly regulated through next-generation sequencing are
also found significantly regulated in the microarray experi-
ment (Additional file 2: Figure S1 and Additional file 1:
Table S3).
In order to further validate the sequencing results
obtained here, we performed qPCR to test the expres-
sion levels of hsa-miR-4521, hsa-miR-145-3p and hsa-
miR-222-5p. Indeed, all microRNAs were validated as
down-regulated in agreement with the sequencing data
(Figure 1C, adj.p-val ≤ 0.05). The expression levels of
hsa-miR-145-5p and hsa-miR-222-3p were found either
not changed or slightly up by qPCR (Figure 1C). This
suggests that one strand for these microRNAs is specific-
ally down-regulated under hypoxic conditions and may
have been functional as compared to the other strand.
Role of HIF in microRNA regulation under hypoxia
Direct regulation of microRNA expression by HIF-1α
and HIF-2α in MCF-7 was assessed by ChIP-seq, while
stabilization of the two proteins in the same cells under
hypoxia has been published previously [25,26]. We used
the 500 published high-stringency HIF binding sites [29]
in order to look for microRNAs that map to within
50 kb of each binding site. Gene Set Enrichment Analysis
(GSEA) against the fold change by hypoxia at each of the
three time points shows a weak enrichment for HIF-
binding microRNAs amongst those up-regulated by hyp-
oxia, which becomes more apparent at the longer timepoints (Figure 2A-C). The heat map (Figure 2D) shows
the fold change at each time point for each microRNA
locus containing a HIF binding site. The most up-
regulated microRNA containing a HIF-binding site is
indeed hsa-miR-210-3p, but there are clearly other micro-
RNAs (Additional file 1: Table S4). In Figure 2E and F we
show the tracks for two loci of particular interest, MIR30D
and MIR27A, which are near the top of the list. Indeed,
hsa-miR-30d-5p, hsa-miR-30d-3p and hsa-miR-27a-5p are
significantly up-regulated at 32 h and 48 h of hypoxia
according to our sequencing data. Both microRNA loci
have un-annotated, hypoxia inducible host transcripts that
appear in directional ribo-depleted RNA-seq data pro-
duced by exposing the MCF-7 cells to hypoxia (24 h 1%
hypoxia) [30] and strong HIF-binding ChIP-seq peaks
(Figure 2E and F).
Hsa-miR-27a is within a close distance to other two
microRNAs, hsa-miR-23a and hsa-miR-24-2, whereas
hsa-miR-30d is also very close to hsa-miR-30b. They are
reported to be clustered microRNAs that seem to be
transcribed in the same pri-miRNA, which agrees with
our previous observations concerning the host genes for
these microRNAs. Therefore, we checked the expression of
these microRNAs by qPCR, validating the up-regulations
seen in sequencing results for hsa-miR-30d-5p, hsa-
miR-30d-3p and hsa-miR-27a-5p (Figure 3A and B,
adj.p-val ≤ 0.05). In addition we found hsa-miR-27a-3p sig-
nificantly up-regulated across the whole hypoxia time
course, hsa-miR-23a-3p up-regulated at 48 h and hsa-
miR-24-2-5p, hsa-miR-30b-5p and hsa-miR-30b-3p sig-
nificantly up-regulated at 32 and 48 h (Figure 3A and
B, adj-p-val ≤ 0.05). It is worth to mention that hsa-
miR-27a-3p was also found significantly up-regulated
across all hypoxia time course in Agilent microarray data
(Additional file 1: Table S3). All these results would fur-
ther support the role of HIF on regulating the expression
of these microRNA clusters under hypoxic conditions.
The results link genome wide HIF occupancy under
hypoxic conditions to the up-regulation of pri-miRNAs
and mature microRNAs.
Table 2 MicroRNAs found significantly down-regulated in MCF7 cells exposed to hypoxia by analysis of
microRNA-seq data
MicroRNAs significantly down-regulated in hypoxia at 16,32 and 48 h (adj.p-val ≤ 0.05)
miRNAs FC H16h adj.p-val FC H32h adj.p-val FC H48h adj.p-val
hsa-miR-145-3p 0.16 5.60E-06 0.13 1.23E-07 0.10 1.16E-08
hsa-miR-222-5p 0.41 0.02943717 0.34 0.000541974 0.30 7.58E-05
hsa-miR-4521 0.16 2.29E-07 0.09 9.76E-12 0.09 7.42E-12
MicroRNAs significantly down-regulated in hypoxia at 16 and 32 h (adj.p-val ≤ 0.05)
miRNAs FC H16h adj.p-val FC H32h adj.p-val FC H48h adj.p-val
hsa-miR-29b-1-5p 0.41 0.02943717 0.53 0.049237065 0.64 0.160459153
MicroRNAs significantly down-regulated in hypoxia at 32 and 48 h (adj.p-val ≤ 0.05)
miRNAs FC H16h adj.p-val FC H32h adj.p-val FC H48h adj.p-val
hsa-let-7f-1-3p 0.58 0.618581404 0.37 0.003952372 0.46 0.02280333
hsa-miR-1260a 0.59 0.676561681 0.25 0.000224356 0.45 0.027900682
hsa-miR-1260b 0.52 0.480646057 0.19 1.21E-05 0.38 0.008394683
hsa-miR-1275 0.98 0.983716794 0.46 0.038509311 0.25 0.000158578
hsa-miR-15b-3p 0.92 0.962873516 0.32 0.003952372 0.36 0.007476629
hsa-miR-19a-3p 1.59 0.866491946 0.37 0.036219879 0.37 0.025453723
hsa-miR-19b-3p 1.55 0.866491946 0.33 0.018184509 0.34 0.016879484
hsa-miR-19b-1-5p 0.53 0.472759683 0.33 0.002596151 0.31 0.000890148
hsa-miR-22-3p 1.39 0.904640745 0.41 0.039758527 0.40 0.026856552
hsa-miR-221-5p 0.82 0.904640745 0.54 0.041249481 0.36 0.000264743
hsa-miR-23a-5p 0.35 0.225229269 0.30 0.016836038 0.16 0.000197073
hsa-miR-23b-5p 0.46 0.059350069 0.43 0.003952372 0.43 0.002649597
hsa-miR-296-3p 0.46 0.298355571 0.34 0.003952372 0.21 1.55E-05
hsa-miR-32-3p 0.86 0.955522425 0.48 0.036493987 0.33 0.000822847
hsa-miR-33a-3p 0.44 0.618581404 0.22 0.012191307 0.17 0.003599729
hsa-miR-3613-5p 0.88 0.962873516 0.36 0.002314 0.38 0.002622677
hsa-miR-424-3p 0.64 0.720598475 0.31 0.000695205 0.23 9.65E-06
hsa-miR-4466 0.53 0.50269118 0.13 1.23E-07 0.19 1.72E-05
hsa-miR-455-3p 1.29 0.904640745 0.46 0.026536474 0.45 0.016879484
hsa-miR-505-5p 0.73 0.866491946 0.36 0.001669409 0.35 0.000890148
hsa-miR-573 0.66 0.773087527 0.18 1.88E-07 0.09 4.29E-12
hsa-miR-92a-1-5p 0.59 0.720598475 0.22 0.000120735 0.20 2.52E-05
hsa-miR-93-3p 0.63 0.720598475 0.42 0.016836038 0.37 0.003599729
hsa-miR-940 1.11 0.962873516 0.32 0.002314 0.27 0.000255512
MicroRNAs in each section of the table are arranged in numerical order for ease of reading. Fold-change in linear scale (FC) and adjusted p value (adj.p-val) are
shown for each microRNA at each hypoxia time. MicroRNAs which regulation by hypoxia has not been reported before have been highlighted in bold.
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hypoxia gene signature in breast cancer samples
Previously, we have reported the direct correlation of
hsa-miR-210-3p with a hypoxia score based on the
expression of 99 genes [31] in a series of breast cancer
tumours [27]. Since microRNA expression profiles for
this breast cancer series have been recently published
(GSE22220) [32], we have investigated the correlation of
the hypoxia score with microRNA expression in this series.
Among the positively correlated microRNAs to hypoxia inbreast cancer (Spearman rank test, adj.p-val ≤ 0.05), there
are two microRNAs that overlap with our list of hypoxia
induced microRNAs: hsa-miR-210-3p and hsa-miR-27a-3p,
which is derived from the MIR27A cluster (see Table 3).
Interestingly another microRNA generated from the same
cluster, hsa-miR-24-3p, is also directly correlated to hyp-
oxia in breast cancer (Table 3). Although no regulation by
hypoxia has been detected for this microRNA in our
MCF-7 cells, this could be due to the fact that hsa-

















Figure 2 Hypoxically induced microRNAs are transcriptionally regulated by HIF. microRNAs within 50 kb of a HIF-binding site were analysed
by GSEA using the pan-genomic microRNA datasets of fold change in expression at (A) 16 hours, (B) 32 hours and (C) 48 hours. (D) Heat map
showing fold change after differing periods of hypoxia for all HIF-binding microRNAs. (E & F) RNA-seq and ChIP-seq tracks showing HIF binding and
transcriptional up-regulation of previously un-annotated transcripts hosting the loci MIR27A and MIR30D. Red tracks show strand-specific ribo- RNA-seq
in normoxia and hypoxia. RNA-seq reads are split between ones mapping in the plus and minus strand under normoxia or hypoxia. Purple tracks show
ChIP-seq using antibodies against the indicated HIF subunit.
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mechanisms that contribute to its final levels. However
it is important to highlight that three of the microRNAs
for which we have identified a HIF binding site at a
close distance appear to be directly correlated to hyp-
oxia in breast cancer. This data demonstrates for the
first time that hsa-miR-27a-3p and hsa-miR-24-3p are
regulated by hypoxia in vivo in breast cancer and that
this regulation is possibly dependent on HIF.
microRNAs encoded within host genes
Some of the microRNAs found up- or down-regulated
under hypoxia are located within intronic regions ofprotein coding genes. Therefore, we generated mRNA
expression profiles of the same time course samples
using Illumina arrays. If only considering microRNAs
with a unique genomic position, we found 185 micro-
RNAs encoded within 120 host genes that were detected
in our microarray experiment (Additional file 1: Table S5).
No correlation was found between microRNA expression
and host gene expression at any hypoxia time point
(Spearman rank correlation: 0.137 (P.val = 0.0613) at
16 h; -0.0949 (P.val = 0.1961) at 32 h; -0.0127 (P.val = 0.8621)
at 48 h). Looking at the expression of genes containing
microRNAs, we observed that they do not show a lot of
variation. When dividing them in 3 groups according to
27 3 23 3 24 3
27 5 23 5 24 2 5
30 5 30 5
30 3 30 3
A)
B)
Figure 3 (See legend on next page.)
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Figure 3 Hypoxic regulation of microRNAs clustered to MIR27A and MIR30D. QPCR was used to assess the expression of both 5p and 3p arms
of two microRNA clusters that are within 50 kb of a HIF-binding site: hsa-miR-27a, hsa-miR-23a and hsa-miR-24-2 (A) and hsa-miR-30d and hsa-miR-30b
(B). Fold-changes (in linear scale) obtained for each microRNA at each time point relative to normoxia control are represented in boxplots (*significant
fold-change compared to normoxia after ANOVA followed by pairwise t-test, adj.p-val≤ 0.05).
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down-regulated or without changes in hypoxia, the average
fold-change of the up- or down-regulated groups is not
very different to the group without changes (Figure 4A),
suggesting that these genes are very lightly regulated by
hypoxia at transcriptional level. For each of the group
of genes, we represented boxplots with the expression
of the microRNAs they contained (Figure 4B), showing
the lack of correlation between the average fold-change
of the microRNAs and the average fold-change of the
corresponding host genes. Similarly from the microRNA
point of view, we divided the microRNAs located within a
host gene in three groups depending on their fold-change
expression at 32 h and 48 h of hypoxia (up-regulated,
down-regulated or no change, Figure 4C). Then for each
group of microRNAs, we represented the fold-changes
of the corresponding host genes (Figure 4D). While up-
regulated and down-regulated microRNAs showed an
average fold-change of 2 and 0.5 respectively (Figure 4C),
the average fold-change of the corresponding host
genes was very similar and close to 1 for both groups
(Figure 4D). The picture is the same when Agilent
microarray data are used to determine microRNA expres-
sion fold changes instead of small RNA-seq (Additional
file 3: Figure S2). Detailed examples of these relationships
can be seen in Additional file 1: Table S6. In general we
observed around a 50% agreement between microRNA
and host gene expression. In order to gain more infor-
mation, we focused on cases where there is no correl-
ation between microRNA and host gene expression and
performed additional validations. The first example is
hsa-miR-942-5p, found significantly up-regulated at 32
and 48 h, whereas its hosting gene TTF2 was significantly
down-regulated in array data (Additional file 1: Tables S5
and S6). Indeed TTF2 was found significantly down-Table 3 MicroRNAs found up-regulated in hypoxic MCF-7





MicroRNAs are arranged according to significance to hypoxia signature in breast
cancer. Correlation coefficient (rho) and adjusted p value (adj.p-val) are shown.
†Not significantly regulated in hypoxia in MCF-7 cells. However it is part with
hsa-miR-27a-3p of the same cluster, which has a HIF binding site mapped close.regulated in hypoxia by qPCR (adj.p-val ≤ 0.05, data not
shown). Also hsa-miR-3140-3p is up-regulated in sequen-
cing data whereas the host gene FBXW7 is down-regulated
in array data (Additional file 1: Tables S5 and S6). FBXW7
has four isoforms and only two would contain MIR3140
within its sequence (Figure 5A). We designed a pair of
primers (Figure 5A, F1 and R1) that would amplify three
isoforms, including two that do not include the MIR3140
locus and a pair of primers specific for the two isoforms
containing MIR3140 (Figure 5A, F2 and R2). All products
were found significantly down-regulated in hypoxia by
qPCR (Figure 5A, adj.p-val ≤ 0.05).
Another interesting example is the cluster composed
by hsa-miR-106b and hsa-miR-93 and their host gene
MCM7. The microRNA sequencing data showed a sig-
nificant up-regulation of hsa-miR-106b-3p and down-
regulation of hsa-miR-93-3p at 32 h and 48 h of hypoxia,
whereasMCM7 was significantly down-regulated according
to array data (Additional file 1: Tables S5 and S6). MCM7
has two isoforms and was confirmed as significantly down-
regulated in hypoxia by qPCR when primers able to amplify
both isoforms were used (Figure 5B, primers F0 and R0).
However when using specific primers for testing the
expression of each isoform separately, we found one
isoform significantly down-regulated at all hypoxia times
(Figure 5B, primers F1 and R1, adj.p-val ≤ 0.05) whereas
the other isoform was significantly up-regulated at 32 and
48 h (Figure 5B, primers F2 and R2, adj.p-val ≤ 0.05). This
isoform specific regulation would match the regulation
of the microRNAs provided they are processed from
preferred isoforms.
Changes in expression of microRNA processing genes due
to hypoxia
Overall there is a certain degree of coordination between
host gene and microRNA expression under hypoxia but
also discrepancy. This suggests that other factors may be
involved in the changes observed in mature microRNA
expression under hypoxia. We used the gene expression
profiles to specifically monitor any change in the ex-
pression of genes coding for proteins involved in the
microRNA maturation pathway in hypoxic MCF-7 cells.
Indeed, significant changes (see Additional file 1: Table S7,
adj.p-val < 0.05) were detected in the expression of several
genes, including DDX5 (encoding P68 which forms part of
the protein complex lead by DROSHA), XPO5 and RAN





Figure 4 Low correlation between microRNA and corresponding host gene expression. Expression of genes hosting microRNAs was obtained
from microarray data and expression of corresponding microRNAs was obtained from microRNA-seq data. The hypoxic regulation at 32 h and 48 h for
both groups was then compared from two different perspectives. First, hosting genes were sorted in 3 groups at each time point: significantly
down-regulated (down), not significantly regulated (unv) and significantly up-regulated (up). The fold-change distribution for each group of
genes at 32 h and 48 h of hypoxia compared to normoxia is shown in boxplots (A). For each group of genes, the fold-change distribution of
corresponding microRNAs at 32 h and 48 h compared to normoxia is also shown in boxplots for comparison (B). Second, microRNAs hosted
within genes were sorted in 3 groups according to their hypoxic regulation at 32 h and 48 h: significantly down-regulated (down), not significantly
regulated (unv) and significantly up-regulated (up). The fold-change distribution for each group of microRNAs at 32 h and 48 h of hypoxia compared
to normoxia is shown in boxplots (C). For each group of microRNAs, the fold-change distribution of corresponding host genes at 32 h and
48 h compared to normoxia is also shown in boxplots for comparison (D). All fold-change distributions are shown in linear scale.
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the cytoplasm), DICER and EIF2C2 and EIF2C4 (encod-
ing AGO2 and AGO4, respectively, both associated to
RISC complex). We also found that some of these
changes were HIF-1α and HIF-2α dependent based on
previous data, in which gene expression regulations
dependent on these transcription factors were studied
through microarray profiles after short interfering (si)
RNA-based suppression of HIF subunits [26]. In order
to validate these results, we performed qPCR using the
MCF-7 hypoxia time course, and two HIF-1α and HIF-
2α siRNA sample sets (Figure 6). Indeed, we could con-
firm a significant down-regulation of DDX5, XPO5, RAN,EIF2C2 and DICER consistently across the hypoxia time
course in MCF-7 cells, as well as a significant up-
regulation of EIF2C4 (Figure 6). We also confirmed by
qPCR a significant up-regulation of both genes DICER
and EIF2C2 when HIF-1α and HIF-2α are silenced in
MCF-7 compared to the control, in both independent
sample sets (Figure 6). Concerning EIF2C4, its expression
was found significantly down-regulated upon HIF-1α
silencing (Figure 6). Therefore the down-regulation of
DICER and EIF2C2 under hypoxia is dependent on both
HIF-1α and HIF-2α, whereas the up-regulation of EIF2C4
seems to be only dependent on HIF-1α. Changes observed











Figure 5 Examples of lack of correlation between microRNA and host gene expression. QPCR was used to assess the expression of two
genes hosting microRNAs: FBXW7 (A) and MCM7 (B). Primers able to anneal to different isoforms were used in order to monitor isoform-specific
expression. Fold-changes (in linear scale) obtained for each transcript at each hypoxia time point relative to normoxia control are represented in
boxplots (*significant fold-change compared to normoxia after ANOVA followed by pairwise t-test, adj.p-val≤ 0.05). For FBXW7 and MCM7, diagrams
showing the different isoforms and the location of microRNAs and pairs of primers designed for detecting each isoform are included in (A) and (B),
respectively (forward and reverse primers are designed as F and R, respectively).
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not change in the HIF siRNA experiments (Figure 6).
Despite the fact that some of the changes observed
under hypoxia for these genes are HIF dependent, we
could not find any high stringency HIF binding site close
to any of these genes in our datasets. Since the down-
regulation of DICER in hypoxic MCF-7 cells is the most
strongly associated to HIF among the genes involved in
microRNA processing, we decided to test whether this
change was also observed in vivo. We used the gene ex-
pression data generated for the same breast cancer serieswe have referred in the previous section (GSE22220) [32]
and investigated the correlation of DICER expression with
the hypoxia score based on the expression of 99 genes
(univariate analysis) [31]. Interestingly, we found that
the expression of DICER was significantly inverse cor-
related to hypoxia in breast cancer (univariate analysis:
rho = -0.37, pval = 3.e-08), meaning that the expression
of DICER is lower as hypoxia increases. Therefore we
show that DICER is also down-regulated under hypoxia
in vivo in breast cancer and that this regulation is possibly
dependent on HIF although not in a direct manner.
Figure 6 (See legend on next page.)
Camps et al. Molecular Cancer 2014, 13:28 Page 13 of 21
http://www.molecular-cancer.com/content/13/1/28
(See figure on previous page.)
Figure 6 Hypoxia regulates genes involved in microRNA processing pathway in a HIF-dependent manner. QPCR was performed to monitor
the expression of genes involved in the microRNA processing pathway. Hypoxia MCF-7 time course and 2 sets of HIF-1α and HIF-2α siRNA in
MCF-7 were analysed. Fold-changes (in linear scale) obtained for each gene at each time point relative to corresponding control are represented in
boxplots (*significant fold-change compared to normoxia after ANOVA followed by pairwise t-test, adj.p-val ≤ 0.05; † adj.p-val ≤0.08).
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We have presented a very robustly analysed, deep se-
quencing based microRNA expression profile of a three
point hypoxia time course, representing a first for MCF-
7 cells. To our knowledge, this is the first time such an
in-depth study has been performed and all the data is
publicly available at GEO (reference series: GSE47534)
as a resource for future investigations. We have shown
that the number of hypoxia regulated microRNAs in-
creases in time, with a clear breakpoint between 16 h
and 32 h. This is in agreement with Kulshreshtha and
colleagues [16], although spotted microarrays provided a
limitation of their study. Overall, 69 microRNAs were
found regulated in more than one time point, of which
56 are novel for hypoxia. In particular, we report here
the down-regulation of hsa-miR-4521, hsa-miR-145-3p
and hsa-miR-222-5p at 16 h, 32 h and 48 h of hypoxia.
These changes were detected along the whole time course
in addition to the up-regulation of hsa-miR-210-3p.
Therefore, these as yet largely uncharacterised micro-
RNAs could play an important role in hypoxia. Since
hsa-miR-210-3p has proved to be a master regulator
(for a review see [33]) and an independent prognostic
factor in breast cancer [27], it will be worth to assess
these microRNAs for their relevance as breast cancer
prognostic markers in the future. A top predicted target
of hsa-miR-145-3p in miRBase (DIANA MICRO -T and
MIRDB) is CCNC (cyclin C), a possible tumor suppressor
gene [34], while a top predicted target for hsa-miR-
4521 is FOXM1 (miRBase, using DIANA MICRO -T
and MIRDB), which controls cell cycle gene expression
[35]. It is therefore conceivable that the down-regulation
of these microRNAs does influence cell proliferation.
In addition, we report other microRNAs that are con-
sistently regulated at 32 h and 48 h in MCF-7 cells. Some
of these changes have been reported before, using other
cell types and conditions, such as the up-regulation of
hsa-miR-151-3p in nasopharyngeal carcinoma cells [15],
hsa-miR-30d-5p in both nasopharyngeal carcinoma cells
and HT29 colon cancer cells [12,15], hsa-miR-140-3p and
hsa-miR-143-3p in human primary pulmonary artery
smooth muscle cells (PASMCs) [18], hsa-miR-27a-3p and
hsa-192-5p in colon and breast cancer cells and PASMCs
[16,18], and hsa-miR-1246 and hsa-miR-215-5p in colonic
epithelial cells [20]. Also the down-regulation of hsa-miR-
32-3p and hsa-miR-505-5p has been reported in HUVEC
cells [14]. In general, the overlap between studies is
limited due to the usage of different cell lines andhypoxia conditions, as well as to the variety of plat-
forms used for the measurement of microRNA expres-
sion. It is also not uncommon to find microRNAs for
which contrasting regulation under hypoxia has been
described. To support this, an extensive comparison of
our data at each hypoxia time point with previous stud-
ies [11-16,18-20] has been included in Additional file 1:
Table S9.
It is known that prolonged hypoxia leads to generation
of free radicals and therefore to oxidative stress. Some of
the microRNAs found to be regulated by hypoxia in this
study have been reported in the context of oxidative
stress. For instance, hsa-miR-210-3p regulates mitochon-
drial activity under hypoxia by targeting ISCU1, ISCU2,
COX10, SDHD and NDUFA4 and also affects the pro-
duction of Reactive Oxygen Species (ROS). Indeed it has
been found that hypoxia increases ROS levels in cancer
cells and that this effect can be reversed by blocking
miR-210-3p. However ROS levels are not altered by
hypoxia in endothelial cells but they are increased upon
hsa-miR-210-3p abrogation. In other cells such as differ-
entiated skeletal muscle cells, neonatal rat cardiomyocytes
and H9c2 cells, miR-210-3p expression reduces mito-
chondrial ROS production and decreases mitochondrial
mass (all reviewed in [36]). Therefore further work is
needed to understand the role of this microRNA in the
regulation of ROS levels. It has been also reported that
the treatment of auditory cells with the potent oxidant
t-BHP down-regulates the expression of hsa-miR-203a
and hsa-miR-28-3p (which we found up-regulated in
hypoxia at 32 h and 48 h, Table 1) and hsa-miR-92a-1-5p
(which we found down-regulated at 32 h and 48 h of
hypoxia, Table 2) [37]. Furthermore, the expression of
the hypoxia regulated hsa-miR-143-3p, hsa-miR-27a-3p
(Table 1) and hsa-miR-22-3p (Table 2) has been described
to be altered in human fibroblasts after treatment with
peroxide and etoposide (only hsa-miR-27a-3p) [38].
The next question to address was the role of HIF in
this process as a key mediator of the transcriptional
response to hypoxia. In previous work [29,39], it was
demonstrated that HIF-1α and HIF-2α binding to DNA
is associated with up-regulation of nearby genes, but the
association of binding sites and microRNA expression at
whole genome level had not been explored so far. Only
two microRNAs, hsa-miR-26a and hsa-miR-210, have
been shown to have closely positioned HIF binding sites
by HIF-1α chromatin immunoprecipitation (ChIP) [16].
Here, we used HIF-1α and HIF-2α ChIP-seq data
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close to microRNAs at genome-wide level. GSEA using
up- and down-regulated microRNAs revealed an associ-
ation between proximity of HIF binding and up-
regulation. This is further supported when comparing
our data to previous studies, since HIF binding sites
identified here are closer to microRNAs reported to be
up-regulated rather than down-regulated in hypoxia
(Additional file 1: Table S9). We showed that functionally
important, up-regulated microRNAs have HIF binding
sites, such as hsa-miR-27a and hsa-miR-30d. Both micro-
RNAs are involved in cancer progression, hsa-miR-30d-5p
by targeting TP53 [40] and hsa-miR-27a-3p by regulating
a number of transcription factors such as ZBTB10
[41,42]. The HIF dependence of the microRNA cluster
composed by hsa-miR-27a, hsa-miR-23a and hsa-miR-
24-2 had been discussed earlier through the prediction of
a conserved HIF binding site within the promoter region
of this microRNA cluster [43]. In addition to the HIF
binding site, we show here that the expression of hsa-
miR-27a-3p and hsa-miR-24-3p is positively correlated
with a hypoxia score based on the expression of 99 genes
in a series of breast cancer samples. This would reinforce
the role of HIF in regulating microRNAs in breast cancer
and other solid tumours, and the idea that hypoxia could
be a key factor in microRNA modulation in cancer [16].
Nevertheless, not all the microRNAs with HIF binding
sites in their proximity were up-regulated under hypoxia.
We also found some discrepancies between microRNA
and host gene expression (where microRNAs are located
within intragenic regions), and have shown in the example
of the MCM7 locus, that differential expression of tran-
script isoforms may play a role in these discrepancies. In
general, host gene expression was less responsive to
hypoxia than changes in levels of mature microRNA
forms. This is in agreement with findings that other
levels of microRNA regulation take place. Indeed, it has
been shown that hypoxia is able to regulate the expression
and activity of proteins involved in the post-transcriptional
microRNA processing. In HUVEC cells exposed to chronic
hypoxia (24 h), several components of the processing
pathway as DGCR8, EXPORTIN5, DICER, TRBP, AGO1
and AGO2 are significantly down-regulated at both
protein and mRNA level [14]. Moreover, the decrease
of DICER protein and mRNA levels has been confirmed
in vivo in several tissues from mice exposed to chronic
hypoxia and also low mRNA levels for DICER have
been observed in rat models for pulmonary arterial
hypertension [44]. On the other hand, it has been shown
in PASMCs that AGO2 can be subjected to a post-
translational modification that increases its stability and
translocation rate to the stress granules. Since AGO2 is
the key mediator of microRNA function, this modification
of AGO2 has an impact on microRNA – target interaction[18]. Some of our findings are in agreement with these
recent reports, such as the down-regulation of XPO5,
DICER and AGO2 transcripts. In addition, we found a
significant down-regulation of DDX5 and RAN, and a
significant increase in AGO4 transcript. We have further
explored the regulation of these genes under hypoxia in
other 13 cell lines by using expression data available in
GEO from other hypoxia studies (see Additional file 1:
Table S10). These cell lines were exposed to hypoxia
(mostly 1% Oxygen) for a period ranging between 16 h
and 72 h. In general we can see that DICER, DDX5, XPO5
and RAN are down-regulated at transcriptional level in
several cell lines but not all, suggesting that these changes
have a component of cell specificity (Additional file 1:
Table S10). EIF2C2 (AGO2) transcript presents contrast-
ing regulation depending on the cell line whereas EIF2C4
(AGO4) appears to be up-regulated in two other cell lines
(HUVEC and prostate cancer at 48 h and 72 h of hypoxia,
respectively. Additional file 1: Table S10). Although the
transcript levels do not always correspond to protein
levels, previous studies in hypoxia (as we have just referred
above) show a good concordance between both for several
of the microRNA processing genes. DDX5 acts also as a
transcription cofactor and is required for cell proliferation
[45], for induction of TP53 dependent p21 (CDKN1A)
expression after DNA damage [46] and NOTCH1 sig-
nalling [47]. The effect of AGO4 on microRNA levels is
not clear, but it could provide a further enhancement of
RISC complex mediated effects on translation. Despite
the fact that several members of the processing machinery
are down-regulated, recent work has shown that hydroxyl-
ation [18] and phosphorylation [24] of AGO2 affect the
microRNA maturation process.
The role of HIF in the regulation of the genes involved
in the microRNA processing has not been thoroughly
studied. Using HIF siRNA on MCF-7 cells, we showed
that indeed DICER and AGO2 transcriptional down-
regulations in hypoxia are HIF-1α and HIF-2α dependent,
while this dependency was not observed in HUVEC cells
[14]. Also, AGO4 transcriptional up-regulation in hypoxia
is HIF-1α dependent. Since no HIF binding site was
mapped close to these genes in our datasets, the regula-
tion is likely to be indirect and in line with the observation
that in breast cancer samples low levels of DICER are
associated with a hypoxia signature.
HIF is an important factor in the pathophysiology of
cancer and the identification of the mechanisms through
which it mediates microRNA expression regulation will
lead to a better understanding of this complex pathway.
In addition, establishing a complete repertoire of hypoxia
regulated microRNAs will lead to more detailed analysis
of large scale cancer sample datasets for microRNA-target
gene relationships [48] and lead to the development of
advanced prognostic assays and therapeutic approaches.
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Next generation sequencing based methods are state of
the art for microRNA profiling. Here we applied this
methodology and identified a high number of micro-
RNAs that are regulated by hypoxia in MCF-7 cells,
including novel hypoxia regulated microRNAs detected
in this study that are candidates for developing breast
cancer prognostic assays. The microRNA data were in-
tegrated with mRNA and HIF ChIP-seq data to show
genome wide correlation between HIF binding and
microRNA regulation for the first time. In addition, we
show that hsa-miR-27a-3p and hsa-miR-24-3p, for which
we have identified a HIF binding site at close distance, are
positively correlated to hypoxia in breast cancer. Analysis of
microRNA-host gene expression correlation supports the
idea that posttranscriptional mechanisms for microRNA
expression regulation are in action under hypoxia, and we
provide evidence that HIF can play a role by modulating
the expression levels of microRNA processing genes such
as the down-regulation of DICER. Moreover we report an
inverse correlation of DICER expression to hypoxia
in breast cancer. Therefore, HIF, as a key factor of the
hypoxia transcriptional response plays a role in the
regulation of microRNAs either directly through binding
to microRNA loci, or indirectly through regulating micro-
RNA processing gene expression and pathways leading to
posttranslational modifications of AGO2.
Methods
Cell culture and hypoxia exposure
Breast adenocarcinoma cell line MCF-7 cells were grown
in Dulbecco’s Modified Eagle Medium supplemented
with 10% fetal bovine serum (Sigma-Aldrich, St Loius,
Missouri, USA) and 2 mmol/L of L-glutamine. Exposure
of cell cultures to hypoxia (1% Oxygen) was undertaken
in an In vivo2 Hypoxia Work Station (Ruskin Technologies,
Pencoed, UK) in parallel with cells maintained in normoxic
conditions (21% oxygen). Cells were recovered after 16 h,
32 h and 48 h of exposure to hypoxia. All experiments were
done in triplicate from independent cell cultures.
RNA extraction
RNA was extracted from cells using the miRVana
miRNA Isolation Kit (Ambion, Life Technologies, Carlsbad,
California, USA). RNA quality and abundance were deter-
mined after extraction using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, California, USA) and a
Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific, Waltham, Massachusetts, USA), respectively.
Preparation of microRNA libraries for next-generation
sequencing
For each experimental condition (normoxia, 16 h hypoxia,
32 h hypoxia, 48 h hypoxia), small RNA libraries for next-generation sequencing were prepared from RNA samples
obtained from two biological replicates. Each library was
prepared from the 20 to 30 nucleotide RNA fraction. This
was isolated from 2 μg of total RNA after being run in a
15% urea-TBE gel (Invitrogen, Life technologies, Carlsbad,
California, USA) for 1 h at 200 V. The RNA contained in
the excised band was eluted in 300 μl of 0.3 M NaCl by
4 h of constant rotation at room temperature. The elute
was separated from the gel debris using a Spin-X-column
(Thermo Fisher Scientific, Waltham, Massachusetts, USA)
and RNA was precipitated by adding 750 μl of 100%
ethanol and 3 μl of glycogen (1 mg/ml) and incubating
for 30 minutes at -80°C. The precipitated RNA was cen-
trifuged at 14,000 rpm for 25 minutes at 4°C, washed with
75% ethanol, air dried and resuspended in 5 μl of RNAse-
free water. This material was used to prepare sequencing
libraries using the DGE-small RNA sample preparation kit
(v1.5) from Illumina (Illumina inc., San Diego, CA, USA )
according to the protocol provided by the manufacturer.
The abundance of the libraries was measured using Qubit
dsDNA HS Assay kit and a Qubit 2.0 fluorometer (both
from Life technologies, Carlsbad, California, USA). The
size of the products contained in the libraries was assessed
with a DNA 1000 chip and an Agilent 2100 Bioanalyser
(both from Agilent Technologies, Santa Clara, California,
USA). The libraries were sequenced using an Illumina
Hiseq sequencer according to the manufacture’s standard
protocols at 36 bp read length.Alignment and analysis of microRNA next-generation
sequencing data
Small RNA sequencing data were processed from raw
FASTQ files and analysed using the Kraken pipeline
(http://www.ebi.ac.uk/research/enright/software/kraken)
[49]. The 3’ adaptors were stripped using the criteria:
12-nt alignment stretch with no more than 2 mismatches
and no gaps. The reads were then filtered for low-
complexity regions and the remaining reads were size-
selected for 18-26nt, resulting in inclusion of more than
75% of reads on average for each sample (Additional
file 1: Table S1). A file with unique reads and their
corresponding counts was generated for each sample.
The final processed unique reads were mapped to the
human genome (hg19 based on Ensembl v64 [50]) using
Bowtie 0.12.7 [51] allowing for two mismatches and using
the best alignment stratum option. Reads mapped to more
than 20 loci were discarded. Mapped reads were classified
and counted based on genomic annotations (RNAs,
coding genes, pseudogenes and repeats) obtained from
Ensembl v64 (Additional file 1: Table S1). For reads
mapping to multiple loci, counts were divided by total
number of reads. The sense and antisense distribution
of mapped reads across all chromosomes was also analysed.
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tween mapped reads and human mature microRNAs
(based on miRBase v17 [52]) was found using the function
findOverlaps available in the Bioconductor GenomicRanges
package (http://bioconductor.org/packages/2.6/bioc/html/
GenomicRanges.html). The normalization and differential
expression was performed with Bioconductor edgeR pack-
age v2.3.57 [53] using both common and tagwise disper-
sion. The significant differentially expressed microRNAs
were determined by an adjusted p value lower than 0.05
based on the Benjamini and Hochberg multiple testing
correction [54]. Data has been submitted to GEO (refer-
ence series: GSE47534; miRNA-seq: GSE47602).
HIF-1α and HIF-2α ChIP-seq analysis
We used the 500 published high-stringency HIF binding
sites [29] in order to look for microRNAs that map to within
50 kb of each binding site. Gene Set Enrichment Analysis
(GSEA) was carried out as described previously [29].
microRNA microarrays
microRNA expression profiles were performed using the
human microRNA microarray V2 (Agilent Technologies,
Santa Clara, California, USA) which contains 723 human
microRNAs (Sanger database V.10.1) and 76 human viral
microRNAs. Three biological replicate samples for each
experimental condition (normoxia, 16 h hypoxia, 32 h hyp-
oxia and 48 h hypoxia) were analysed. Samples were pre-
pared with the Mirna Labelling Reagent and Hybridization
kit (Agilent Technologies, Santa Clara, California, USA)
following the instructions supplied by the manufacturer.
The microarray hybridization was performed at 55°C
for 20 h and at a constant speed rotation of 20 rpm.
The hybridization signals were detected by the Agilent
Microarray scanner G2565BA and quantified using the
Agilent Feature extraction software version 9.5.1 (both
from Agilent Technologies, Santa Clara, California, USA).
A GeneView file including the Total Gene Signal (raw
data) and the Total Gene Error for each of the microRNAs
interrogated on the microarray was generated for all the
samples and used for further analysis. One sample cor-
responding to MCF-7 cells exposed to hypoxia for 16 h
was affected by a random technical problem and had to
be removed due to the bad quality of the scan.
microRNA microarray data analysis
The Total Gene Signal was normalised using a variance
stabilization method described by Huber and colleagues
[55]. Furthermore a detection factor was calculated for
each microRNA in every sample as the following subtrac-
tion: Total Gene Signal - Total Gene Error. A microRNA
was considered detected when the value of this factor was
higher than zero. The normalised data was then filtered
based on the detection factor and on the microRNA class.The minimal requirements for a microRNA to be selected
for further analysis were: (i) detection in at least two
biological replicates of any experimental condition and
(ii) be included as human microRNA in miRBase
(www.mirbase.org). Limma analysis was then performed
to assess independently the effects of 16 h, 32 h and
48 h of hypoxia exposure compared to normoxic con-
trol in microRNA expression levels in MCF-7 cells.
Benjamini and Hochberg method was used to correct
for multiple testing [54]. microRNAs with adjusted p values
lower than 0.05 were considered significantly regulated.
Data has been submitted to GEO (reference series:
GSE47534; miRNA: GSE47532).
Gene expression microarrays
mRNA expression was measured using Illumina
HumanWG-6 v3.0 Expression Bead Chip arrays (Illumina
inc., San Diego, CA, USA). The Illumina platform was
chosen as it performed well in large comparative studies
[56]. Three biological replicate samples for each experi-
mental condition (normoxia, 16 h hypoxia, 32 h hypoxia
and 48 h hypoxia) were analysed. RNA was amplified
using the Illumina Total Prep RNA Amplification Kit
(Ambion, Life Technologies, Carlsbad, California, USA).
Amplified RNA product (850 ng) was hybridised to the
Illumina microarrays using single chamber hybridization
cartridges. Washing, staining and scanning were carried
out as specified in the Illumina Whole Genome Expression
Manual v.1.
Gene expression microarray data analysis
Average signal was background subtracted with local
background subtraction (BeadStudio) and consolidated
per gene. Data was quantile normalized in Bioconductor
(www.bioconductor.org) and filtered based on gene de-
tection level using the pvalDet parameter. Only genes
with pvalDet lower than 0.05 in at least 2 replicates of
any of the experimental condition were considered for
further analysis. Limma analysis was then performed to
assess independently the effects of 16 h, 32 h and 48 h
of hypoxia exposure compared to normoxic control in
gene expression levels in MCF-7 cells. Benjamini and
Hochberg method was used to correct for multiple test-
ing [54]. Genes with adjusted p values lower than 0.05
were considered significantly regulated. Data has been
submitted to GEO (reference series: GSE47534; mRNA:
GSE47533).
Datasets from published studies (presented in Additional
file 1: Table S10) have been analysed as described above.
Real time PCR (qPCR) analysis
MicroRNA expression was assessed by qPCR withTaqMan
microRNA assay protocol (Applied Biosystems, Life
Technologies, Carlsbad, California, USA) using 5 ng of
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turer. QPCR was done in a CFX96 real-time PCR detec-
tion system (BioRad, Hercules, California, US). Cycling
conditions included a pre-incubation step (95°C for
3 minutes) and 40 cycles of amplification (95°C for
30 seconds, 60°C for 1 minute). For gene expression, total
RNA (2 μg) was reverse transcribed using the SuperScript
II Reverse Transcription kit, 50 ng of random primers (both
from Invitrogen, Life technologies, Carlsbad, California,
USA) and 0.5 mM dNTP mixture (Bioline, London, UK).
QPCR was done in a CFX96 real-time PCR detection
system using 30 ng of cDNA, 1X iQ SYBR-green supermix
(Biorad, Hercules, California, US) and primers at a final
concentration of 2 mM. Cycling conditions included a
pre-incubation step (95°C for 3 minutes), 40 cycles of
amplification (95°C for 30 seconds, annealing temperature
for 30 seconds and 72°C for 30 seconds) and a melting
curve ( 95°C for 1 minute, 55°C for 1 minute, denaturation
from 55°C to 95°C at 0.5°C/10 seconds increments). Each
reaction was done in triplicate. All primers used are listed
in Additional file 1: Table S8.
Expression values were normalised to the geomet-
rical mean of housekeeping genes RPL11, RPL30 and
RPS6 and fold-changes between treatments and con-
trols were determined by the 2−ΔΔCt method [57] as
implemented in the SLqPCR Bioconductor package
(http://www.bioconductor.org/packages/2.12/bioc/html/
SLqPCR.html). The variance between sample groups
was assessed through the Barlett test for variance. If
variances could be assumed as equal between groups,
significant differences were established using ANOVA
followed by pairwise t-test. If variances could not be
assumed as equal, significant differences were then
assessed using a one way test for equal means
followed by pairwise t-test. After multiple test cor-
rection by Benjamini and Hochberg method [54], re-
sults were considered significant at two levels: with
adjusted p value lower or equal to 0.05 and with ad-
justed p value lower or equal to 0.08. All analysis was
done using R v9 (http://www.r-project.org).Protein immunoblotting
Cells were lysed in urea/SDS buffer (6.7 M urea, 10 mM
Tris-Cl pH 7.4, 10% glycerol, 1% SDS) supplemented
with 1 mM dithiothreitol. Extracts were resolved
by SDS-PAGE, electroblotted onto PVDF membranes
(Millipore) and probed with primary antibodies followed
by HRP-conjugated secondary antibodies. SuperSignal
Chemiluminescent Substrates (Pierce) were used to
visualize immunoreactive species. Antibodies used: anti-
HIF1α 610959 from BD Biosciences, anti-HIF2α 190b
from Peter Ratcliffe Lab, and anti-β-Actin/HPR ab49900
from Abcam.Short interfering RNA treatment of MCF-7 cells
RNA oligonucleotides (Ambion, Life technologies, Carlsbad,
California, USA) were used for siRNA suppression of
individual HIF family members (HIF-1α: sense, CUGAU
GACCAGCAACUUGAtt; antisense, UCAAGUUGCUG
GUCAUCAGtt. HIF-2α; sense, CAGCAUCUUUGAUA
GCAGUtt; antisense, ACUGCUAUCAAAGAUGCUGtt).
A set of oligonucleotides (Ambion, Life technologies,
Carlsbad, California, USA) against a sequence from the
Drosophila melanogaster HIF sequence, which lacks any
substantial sequence similarity with human HIF or other
genes, was used as a negative control (D-HIF: sense,
CCUACAUCCCGAUCGAUGAtt; antisense, UCAUCGA
UCGGGAUGUAGGtt) in one of the experiments. MCF-7
cells were seeded at 30% confluence and grown in normoxic
conditions. Cells were transfected twice with 20 nmol/L
of siRNA at 24 and 48 hours using OligofectAMINE
(Invitrogen, Life technologies, Carlsbad, California, USA)
according to the instructions of the manufacturer. At
55 hours, cells were exposed to 1% oxygen, and after an
additional 16 hours, RNA was extracted. Each siRNA
treatment was done in triplicate as well as the parallel
control using OligofectAMINE reagent alone. The same
protocol was used for the generation of protein extracts.
We ensured that specific and substantial knockdown was
occurring in MCF-7 cells under hypoxia by assaying HIF-α
levels by immunoblotting (as previously described [26]).
Statistical methods
A signature of 99 genes up-regulated under hypoxic
conditions has been derived in head and neck tumors
in vivo and it has been assessed for its prognostic value
in a head and neck and breast cancer data set [31]. Here,
this signature was used to calculate a hypoxic score for a
breast cancer series using the gene expression profiles
(GSE22220) published in [32]. The score is a measure of
the level of expression of genes in the hypoxia signature:
a high positive score reflects a higher than average
expression of the genes in the hypoxia signature and
indicates that the sample is hypoxic, a low negative
score reflects a lower than average expression of the genes
in the hypoxia signature and indicates that the sample is
normoxic [31]. Correlation of microRNA expression from
the same breast cancer series (GSE22220) and hypoxia
score was assessed using Spearman’s rank tests. Statistical
analyses were done using R.
Additional files
Additional file 1: Table S1. MicroRNA-seq analysis. Details are given on
analysis output at different stages. Table S2. MicroRNAs detected in
MCF-7 cells by microRNA-seq. Table S3. MicroRNAs commonly detected
by microRNA-seq and Agilent microRNA arrays in MCF-7 cells. Table S4.
MicroRNA-seq data for microRNAs within 50 kb distance of a HIF binding
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microRNAs encoded within a coding gene sequence. MicroRNA-seq and
mRNA microarray expression of corresponding host gene are provided.
Table S6. Pairs of microRNA and host genes with low coordination
between their expression. Information included as in Table S5. Significant
up- and down-regulations are highlighted in red and green, respectively.
Table S7. Microarray data for genes involved in the microRNA processing.
Table S8. Primers used in the qPCR analysis. Table S9. Comparison with
previously published hypoxia studies. MicroRNAs reported to be hypoxia
regulated in previous studies are included and the regulation is indicated as
up (up-regulated) and down (down-regulated). Concerning our data,
microRNAs found significantly regulated at each hypoxia time (16 h, 32 h
and 48 h) as well as HIF binding sites identified are included. Hypoxic
regulations determined by qPCR are indicated with*. Table S10. Differential
expression of microRNA processing genes using data from published
hypoxia studies. Significant changes are highlighted in red (for
up-regulation) and green (for down-regulation). Note for Table S2 to
Table S7 and Table S10: microRNAs or genes (Tables S7 and S10) are
arranged in numerical order for ease of reading. Fold change (FC) in
linear scale (hypoxia vs normoxia) and p-value before and after multiple test
correction (adj.p-val) are shown for each microRNA and gene at each
hypoxia time (only adj.p-val is shown in Table S10). Platform specified at the
header when multiple data sets are displayed in the same table.
Additional file 2: Figure S1. Validation of microRNA sequencing data
by microRNA microarray. RNA samples were hybridised to Agilent
microRNA arrays (3 biological replicates per condition). We found 228
microRNAs commonly detected between sequencing and microarray
platforms. The fold-changes obtained for each microRNA in each platform
have been compared for each hypoxia time and represented in scatter plots
in log2 scale. MicroRNAs found significantly regulated by sequencing
(adj.p-val < 0.05) are highlighted in colours: in blue if they are only
significantly regulated in the given hypoxia time point or in red if they
are as well significantly regulated in other time points. Solid colours
represent microRNAs that were also found significant by microarray analysis
(limma, adj.p-val < 0.05) in the particular hypoxia time point. The correlation
(pearson) between fold-changes is 0.37 (p-val = 8.47e-09) in hypoxia 16 h,
0.27 (p-val = 2.85e-05) in hypoxia 32 h and 0.30 (p-val = 3.75e-06) in hypoxia
48 h. The correlation is better when only considering the microRNAs found
signficantly regulated by sequencing: 0.43 (p-val = 0.0052) in hypoxia 32 h
and 0.42 (p-val = 0.0019) in hypoxia 48 h.
Additional file 3: Figure S2. Correlation between microRNA expression
obtained from microarray data and corresponding host gene expression.
Expression of genes hosting microRNAs was obtained from microarray
data and expression of corresponding microRNAs was obtained from
microRNA microarray data. The hypoxic regulation at 32 h and 48 h for
both groups was then compared from two different perspectives. First,
hosting genes were sorted in 3 groups at each time point: significantly
down-regulated (down), not significantly regulated (unv) and significantly
up-regulated (up). The fold-change distribution for each group of genes at
32 h and 48 h of hypoxia compared to normoxia is shown in boxplots (A).
For each group of genes, the fold-change distribution of corresponding
microRNAs at 32 h and 48 h compared to normoxia is also shown in
boxplots for comparison (B). Second, microRNAs hosted within genes were
sorted in 3 groups according to their hypoxic regulation at 32 h and 48 h:
significantly down-regulated (down), not significantly regulated (unv) and
significantly up-regulated (up). The fold-change distribution for each group
of microRNAs at 32 h and 48 h of hypoxia compared to normoxia is shown
in boxplots (C). For each group of microRNAs, the fold-change distribution
of corresponding host genes at 32 h and 48 h compared to normoxia is also
shown in boxplots for comparison (D). All fold-change distributions are
shown in linear scale.
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